Table 4:
Treatment statistics (August 2016–August 2017)
| Variable | No.* (%) |
|---|---|
| CPC all-oral cohort (n = 51) | |
| Still on therapy | 18 (35) |
| SOF/VEL | 14 (82) |
| PRoD + RBV | 1 (5) |
| ELB/GRAZ | 3 (17) |
| Patients in whom SVR was evaluable (n = 33) | |
| Discontinued therapy | 2 (4) |
| PRoD + RBV | 1 (50) |
| VEL+SOF | 1 (50) |
| Lost to follow-up | 3 (6) |
| ELB/GRAZ | 2 (67) |
| PRoD + RBV | 1 (33) |
| Achieved SVR | 28 (55) |
| ELB/GRAZ | 4 (14) |
| SOF/LDV | 2 (7) |
| SOF/VEL | 5 (18) |
| SOF/VEL/VOX | 1 (4) |
| G/P | 1 (4) |
| PRoD + RBV | 12 (43) |
| Other | 3 (10) |
| Relapse | 0 (—) |
| SVR rate (ITT) | 28/33 (85) |
| SVR rate (per protocol) | 28/28 (100) |
| Mean person-days of follow-up in SVR cohort | 256 (—) |
| Confirmed cases of reinfection | 0 (—) |
* Unless otherwise noted
CPC = Community pop-up clinic; ELB = Elbasvir; G = Gleacaprevir; GRAZ = Grazoprevir; ITT = Intention to treat; LDV = Ledispavir; P = Pibrentasvir; PRoD = Paritaprevir/ritonavir/ombitasvir + dasabuvir; RBV = Ribavirin; SOF = Sofosbuvir; SVR = Sustained virologic response; VEL = Velpatisvir; Vox = Voxelaprevir